Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Leblebicioglu, Hakan; Arends, Joop; Ozaras, Resat; Corti, Giampaolo; Santos, Lurdes; Boesecke, Christoph; Ustianowski, Andrew; Duberg, Ann-Sofi; Ruta, Simona; Salkic, Nermin; Husa, Petr; Lazarevic, Ivana; Pinede, Juan; Pshenichnaya, Natalia; Tsertswadze, Tengiz; Maticic, Mojca; Puca, Edmond; Abuova, Gulzhan; Gervain, Judit; Bayramli, Ramin; Ahmeti, Salih; Koulentaki, Mairi; Kilani, Badreddine; Vince, Adriana; Negro, Francesco; Sunbul, Mustafa; Salmon, Dominique

doi:10.1016/j.antiviral.2017.12.001

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

Copy For Citation

Leblebicioglu H., Arends J. E., Ozaras R., Corti G., Santos L., Boesecke C., ...More

ANTIVIRAL RESEARCH, vol.150, pp.9-14, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 150
Publication Date: 2018
Doi Number: 10.1016/j.antiviral.2017.12.001
Journal Name: ANTIVIRAL RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.9-14
Keywords: Availability of hepatitis C diagnostics, Therapeutics in European and Eurasia countries, ACCESS, PREVENTION, TBILISI
Ondokuz Mayıs University Affiliated: Yes

Abstract

Background. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.